The burgeoning popularity of tirzepatide , initially for metabolic conditions, is creating significant interest within the British Isles, prompting a notable shift in peptide trends. Obtaining these treatments remains a complex situation , with National Health Service provision currently limited and specialist practices offering therapy at a premiu